Beyond Hypomethylating Agents: Novel Therapies and Targeted Approaches
Open Access
- 7 August 2025
- journal article
- review article
- Published by SAABRON PRESS in Clinical Hematology International
- Vol. 7 (3) , 24-35
Abstract
Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic diseases sharing ineffective hematopoiesis, cytopenias, and a high risk of evolution to acute myeloid leukemia (AML). The current MDS classification systems, such as the International Consensus Classification (ICC) and the WHO 2022 classification, have incorporated molecular and cytogenetic markers to improve the stratification of risk and guide therapy. However, treatment options for high-risk MDS (HR-MDS) remain limited, with hypomethylating agents (HMAs) providing only modest survival benefits. Emerging treatments such as immune checkpoint blockade and novel targeted therapies could further improve patient outcomes. While early excitement was significant, clinical trials of the immune checkpoint inhibitors (ICIs) ipilimumab and durvalumab have produced no definitive results, highlighting the need for better patient selection and combination regimens. Emerging drugs luspatercept and imetelstat have been suggested for lower-risk MDS (LR-MDS) by promoting transfusion independence and global hematologic response. In contrast, exploratory agents such as pevonedistat, magrolimab, and sabatolimab are under further investigation for HR-MDS. The future of MDS treatment currently addresses precision medicine, in which molecular characterization guides therapeutic options. Identification of predictive biomarkers for response to targeted therapies and immunotherapies is crucial to optimize patient outcomes. An integrated, patient-centered approach combining genomics, novel therapeutics, and immunomodulation is therefore essential to address the current needs in MDS management.Keywords
This publication has 72 references indexed in Scilit:
- Ipilimumab for Patients with Relapse after Allogeneic TransplantationNew England Journal of Medicine, 2016
- Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trialThe Lancet Oncology, 2016
- Targeted sequencing identifies patients with preclinical MDS at high risk of disease progressionBlood, 2015
- An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsBlood, 2015
- How we treat higher-risk myelodysplastic syndromesBlood, 2014
- Landscape of genetic lesions in 944 patients with myelodysplastic syndromesLeukemia, 2013
- SomaticSF3B1Mutation in Myelodysplasia with Ring SideroblastsNew England Journal of Medicine, 2011
- The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and TherapyGenes & Cancer, 2010
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancerNature, 2009
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006